Composition for drug targets and application

Abstract

The invention relates to composition for drug targets and an application. The composition comprises a carrier and a drug adopting FKBP10 and PCOLCE genes and / or protein encoded by the genes as drug targets. By means of intervention in FKBP10 and PCOLCE, formation of tissue fibrosis is inhibited, and biological behaviors such as skin fibroblast proliferation, differentiation, apoptosis resistance,secretion of a large quantity of extracellular matrixes and the like are inhibited, so that the effect of treating fibrosis related diseases is achieved.

Description

technical field [0001] The invention belongs to the field of biotechnology, in particular to a composition and application of a drug action target. Background technique [0002] Pathological scar is a skin fibrotic disease that exists all over the world, and its incidence rate varies among different races. Previous reports mentioned that the incidence of pathological scar in the Caucasian population ranges from 5% to 37%. , the incidence rate in patients after conventional surgery is 36-64%, and the incidence rate in deep burn patients can be as high as 91%. Pathological scars are caused by traumatic inflammatory responses, etc., and are characterized by uncontrolled proliferation of fibroblasts (Fb) and excessive production and deposition of a large amount of extracellular matrix (ECM) such as collagen. Metabolic diseases are clinically manifested as scar tissue above the skin surface that does not exceed the scope of the wound, with obvious early congestion, which may be ...

AI Technical Summary

Problems solved by technology

[0006] Limitations of existing prevention and treatment methods for pathological scars: surgical therapy has a high recurrence rate and cannot be applied to patients with large-area scars; compression therapy and silicone products are effective for patients with large-area burns, but only For early prevention, the curative effect on scars that have formed is limited; radiation therapy can cause certain radiation damage to the patient's whole body and local area; cryotherapy is only suitable for small scars, and the treatment can cause skin pigmentation and mild skin atrophy and other complications; glucocorticoid treatment may cause complications such as skin atrophy, depigmentation, telangiectasia, female menstrual disorders, ulceration or calcification at the injection site; laser therapy has a low clinical effective rate and is likely to induce new scars; Antineoplastic drug therapy has a great impact on normal cell metabolism, and the clinical value is not yet clear; tacrolimus, statins, tamoxifen and other drugs have limited clinical efficacy, and the therapeutic target is not yet clear

Images